By combining structural insights with our antibody drug discovery platform and deep understanding of the underlying biology, our scientific outlook is all-encompassing. We consider ideas, findings, and beliefs about validated targets (past and present) and extend them with our critical science to realize great pharmacological potential.
Structural Insights & the Growth Factor Precursor
Unlike traditional approaches, we target growth factors in their inactive precursor, or latent, forms to selectively regulate their activity in the microenvironment of cells and tissues. We applied this extraordinary selectivity across a number of growth factors, including to transforming growth factor beta (TGFβ), and are on the path to achieving novel discoveries.
Learn More About Structural Insights and the Growth Factor Precursor
Technology Platform
Our proprietary platform aids in our development of antibody drugs that apply to targets living in the scientific crossroads of biologically understood and structurally misunderstood.
Recent Publications
View More PublicationsJuly 14, 2021
International Journal of Toxicology
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
May 11, 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
March 22, 2021
International Journal of Toxicology
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
Recent Posters
View More PostersSeptember 2023
Discovery on Target 2023
Discovery and Antifibrotic Activity of an Anti-LTBP-TGFβ1 Inhibitory Antibody
September 2023
Discovery on Target 2023
Discovery and Antifibrotic Activity of an Anti-LTBP-TGFβ1 Inhibitory Antibody
June 2023
Cure SMA 2023 Annual SMA Conference
Effect of Apitegromab on Motor Function and PEDICAT and PROMIS at 36 Months in Patients with Type 2 and Nonambulatory Type 3 Spinal Muscular Atrophy: Combined Presentation of the Phase 2 TOPAZ Study
Partnerships
Help us shed light on the subject. Collaborate with us to uncover enlightened solutions for patients.
“We’re passionate for all
the right reasons.”
Stefan Wawersik
Director, Bioanalytical & Translational Technologies
Join Our Team
Join Our Team
We’re a group of thinkers and doers who fight disease from a new angle.